UA-45667900-1

Wednesday, 22 October 2025

Human Psychology — The Limiting Factor in Dealing with Autism

 

 

When it comes to autism, perhaps the biggest obstacle is not scientific knowledge, but human psychology itself.

We want certainty: lab tests, clear causes, definitive diagnoses, and effective treatments. Yet autism resists all of them. It exists at the intersection of biology, behavior, and more recently culture. It exposes how much of medicine is still filtered through the lens of human perception.

 

The power of belief: Placebo and Nocebo

Autism clinical trials reveal a striking pattern, the placebo group often does surprisingly well. Parents, teachers, and clinicians report improvements in social engagement, eye contact, or irritability even when the child receives no active compound.

That is not fraud — it is psychology. Expectations shape observations. Parents want to see improvement; clinicians want to believe their interventions work (some clinicians even seem to want the interventions of others not to work!). The placebo effect amplifies hope into perceived progress.

The opposite is also true. If a therapy is expected to fail, or cause side effects, people tend to notice negative changes. That is the nocebo effect — our beliefs shaping our biology, or at least our perception of it.

 

Beyond placebo and nocebo: other human effects that shape perception

The placebo and nocebo effects are just the beginning. Human psychology is full of subtle forces that can make a treatment appear to work, or fail, even when biology remains unchanged. These effects are especially powerful in autism research, where progress is measured through behavior rather than lab tests.

 

1. The Hawthorne effect

People often change their behavior simply because they know they are being observed. Parents in a trial may interact more positively with their child, or teachers may give extra encouragement. The child then behaves better—not because of the therapy, but because the social environment has changed.

The Hawthorne effect is a type of human behavior reactivity: individuals modify their behavior simply because they know they are being observed. It was first described in studies during the 1920s at the Hawthorne Works, a Western Electric plant in Illinois, where workers’ productivity appeared to improve under different lighting conditions and work structures. Later analysis suggested that the apparent gains were likely due to the novelty of being studied and the extra attention workers received, rather than the experimental changes themselves.

 

2. Observer expectancy

Researchers and clinicians, consciously or not, tend to see what they expect to see. A therapist who believes a treatment is promising may rate ambiguous behaviors more favorably. Even small cues like tone, enthusiasm or body language can subtly influence outcomes.

 

3. The caregiver effect

When parents believe something is helping, they naturally act differently: calmer, more patient, more hopeful. The child senses this, and behavior improves. The apparent “treatment effect” is really a change in the social dynamic, not the biology of the child.

 

4. Regression to the mean

Children may join studies when their behaviors are at their worst. Over time, things tend to return toward their usual level, whether or not any treatment was effective. Without biological markers, this natural recovery can look like success.

 

5. Confirmation bias

We notice what confirms our hopes and ignore what does not. A parent who wants to see progress will remember good days vividly, while quietly forgetting setbacks. Over time, that bias creates a story of steady improvement—even when change is uneven or minimal.

 

6. Natural maturation

Children grow and change. Speech, self-regulation, and awareness can all improve simply with time and development. Without objective measures, it is hard to tell whether improvement came from therapy or from ordinary maturation.

 

7. The therapeutic alliance

Sometimes, what helps most is the sense of being understood. A caring professional who listens and offers hope can have a measurable calming effect on both parent and child. It feels like progress because it is, psychological progress, but it’s not necessarily biological.

 

8. The expectancy cycle

These forces often combine. Parents, teachers, and researchers all expect improvement, and those expectations subtly reinforce each other. Everyone feels encouraged, interactions improve, and the child responds in kind.

 

Taken together, these human effects can create the illusion of treatment success without any measurable biological change.

They do not make research meaningless, but they remind us that, in autism, we are often studying human perception as much as human biology.

 

Measuring what can’t be measured

Unlike diabetes or infections, autism lacks objective biological markers. There is no blood test, no scan, no lab value that confirms progress. Autism trials rely almost entirely on soft behavioral endpoints like eye contact, social reciprocity, verbal skills, repetitive behaviors.

But these are all subjective judgments. One parent’s “huge improvement” is another’s “slight change.” Even trained clinicians often disagree. This introduces a layer of human variability that overwhelms any small biological signal a treatment might produce.

 

A contrast: When biology speaks clearly

Imagine your nine-year-old child with autism becomes irritable, withdrawn, and starts covering his ears. His behavior worsens rapidly.

You take him to the doctor, who looks in his ear and immediately sees the problem — an infection. The diagnosis itself does not make the pain go away, and the child’s behaviors do not improve simply from being told what is wrong. But after a week on antibiotics, the infection clears. The pain disappears. His sleep normalizes. His behaviors return to baseline.

Here, biology is clear. The cause was physical, the treatment targeted it, and the outcome was measurable. There is no placebo interpretation involved, just the cause-and-effect precision that medicine aspires to.

That clarity is what is usually missing in autism research.

 

The comfort of a diagnosis

By contrast, many adults receiving a mild autism diagnosis report feeling relief,  they finally “understand themselves.” Yet nothing physical has changed. No inflammation has resolved, no neurotransmitter has been balanced. What changed was self-perception.

A diagnosis can provide comfort, identity, and even community. It answers the deeply human need to make sense of who we are. But it is a psychological event, not a biological one.

 

The paradox of mild autism

My mother, a doctor, once remarked how curious it is that so many people are now diagnosed with mild autism — yet there is no therapy or even structured follow-up. The diagnosis is meant to help, but what comes next?

Parents of children with severe autism often feel alienated by this trend. They watch celebrities and influencers describe themselves as autistic for being introverted or socially anxious, while their own children are non-verbal, incontinent, and dependent for life. They feel that the term autism has been stretched so far that it risks losing meaning.

 

When autism is severe, there is less room for subjectivity

In cases of severe autism, the boundaries between perception and reality become clearer. There is less room for interpretation because the behaviors are so obvious, so measurable, and often so disabling that they cannot be mistaken for personality differences.

When a child is non-verbal, does not respond to their name, cannot feed or toilet independently, and shows self-injurious or highly repetitive behaviors, progress can be tracked in concrete ways. A therapy either helps the child communicate a few new words, reduces self-harm, improves sleep, or it does not. There is far less ambiguity.

A parent of a severely autistic child does not need rating scales to know whether their child’s aggression or anxiety has improved, they can see it in daily life. If the child goes from sleeping two hours a night to sleeping eight, that is not a placebo effect. If self-injury stops after an antibiotic or anti-inflammatory, that is a biological clue, not a subjective impression.

Because of this, severe autism may actually offer better opportunities for scientific understanding. The behaviors are consistent and pronounced, and measurable improvements can point to real biological mechanisms—whether immune, metabolic, or neurological.

However, these children are also the most neglected by research. Most autism trials exclude them, preferring verbal, higher-functioning participants who can follow instructions and complete rating scales. Ironically, this biases autism science toward the most subjective end of the spectrum, the very group where human psychology most distorts perception.

If we want to understand autism’s biology, it may be wiser to focus more on those with clear and measurable impairments, where psychology plays a smaller role and biology has a chance to reveal itself.

 

Diagnosis as identity

There is a broader cultural pattern at work. Increasingly, psychiatric labels like ADHD, bipolar disorder, and autism have become identity markers — especially among younger adults. They bring belonging, validation, and sometimes even social capital.

But it raises a question, does the diagnosis help because it changes biology, or because it reshapes how a person feels about their life story?

For some, the label provides understanding. For others, it becomes a kind of permission, a way to explain why life did not turn out to plan. Yet life rarely does, for anyone, neurodiverse or not.

Real life is messy and unpredictable, not like the polished arcs of old Hollywood movies. The narrative a diagnosis provides can feel comforting, but it is ultimately a false framework  an excuse to explain the story, without altering the underlying biology or changing the ending.

 

A broader cultural shift

The rise in self-diagnosed autism overlaps with another social trend, more young people identifying as LGBTQ+. Both movements challenge norms and offer belonging to those who feel different. Both provide a ready-made narrative that transforms uncertainty into identity.

In that sense, autism today has become as much a social phenomenon as a medical one.

 

The human factor in science

Biology is rarely black and white, especially in neuroscience. Each brain is unique, and behavior reflects countless interacting systems. But when objective biomarkers are absent, psychology fills the void — through expectation, perception, and interpretation.

That is why autism remains so difficult to “treat.” Our understanding is constrained not only by biology, but by human psychology — the biases, hopes, and needs that color how we define and measure improvement.

Until we learn to separate biological change from psychological interpretation, human psychology will remain the limiting factor in how we deal with autism.

 






Monday, 13 October 2025

The de-diagnosis of autism begins? And calcium channel blockers considered for ADHD, which type of ADHD and which blocker?

Stockholm – an autism diagnosis hotspot according to the psychologist Sebastian Lundström

Nordic countries often lead the way and after apparently over-diagnosing autism and ADHD they are now eager to de-diagnose it.

I received an article from the British Medical Journal which drew my attention.


Autism and ADHD de-diagnosing services could be rolled out in Sweden—should the US and UK follow suit?

Swedish authorities are considering requests for “de-diagnosis services” for autism and attention deficit/hyperactivity disorder (ADHD) from a new patient group: adults who no longer want their diagnosis.

The proposals come against the backdrop of an ongoing study on around 100 patients, all of whom joined the trial with the hope of getting their diagnostic labels removed. It could see de-diagnosis services rolled out in several of Sweden’s clinics in a matter of months, the study authors told The BMJ.

While “de-diagnosis” is gaining traction in Sweden, clinicians and patient groups who spoke to The BMJ were divided as to whether similar services should be set up in the UK or the US.

What is a de-diagnosis service?

The psychologist Sebastian Lundström, one of the study’s researchers, told The BMJ that his work on this new patient group was prompted by “the sheer number of people with these diagnoses who now are turning into adult age and being told that they can’t join the military services [or] the draft.”

Historically, Swedish citizens with an ADHD or autism diagnosis have been barred from joining the military or working as train drivers without a specific doctor’s note. They must also provide a medical certificate when applying for a driving licence.

At the Preventing Overdiagnosis Conference in Oxford earlier this month, Lundström said that diagnoses had been “assigned by well meaning clinicians” to an increasing number of Swedish children in recent years but that the label could often be “sticky.”

 

Preventing Overdiagnosis Conference in Oxford

In September 2025 there was a conference about overdiagnosis across a wide range of conditions, it was not just about autism and ADHD.

https://www.cebm.ox.ac.uk/preventing-overdiagnosis

But, it did have presentations like:

THE TIDAL WAVE OF ADHD AND AUTISM: INSIGHTS FROM PATIENTS, PROFESSIONALS AND PUBLIC HEALTH

 

Sebastian Lundström’s presentation is available on YouTube. It is very interesting for anyone interested in the skyrocketing level of autism diagnosis.

I have mentioned previously that since in schools in many Western countries more than 20% of kids are now seen as having special educational needs, do not be surprised if autism/ADHD rates eventually hit 20%.  ADHD does look like autism-lite to me and the genetic studies also back this up. So, expect that autism/ADHD reaches 20% of boys.

Now look at Stockholm.

It turns out that in Stockholm 5.9% of teenage boys now have an autism diagnosis and 15% have an ADHD diagnosis. Some will have both.

 

 

Here is the full video for those who think this must be a mistake, or that doctors in Stockholm have gone insane.

 


Now, much to psychiatrists' surprise, adult Swedes are coming forward and trying to delete their autism/ADHD diagnosis from their records. Being Sweden, everything is recorded centrally. In the first 100 cases that were re-evaluated 90% were found to have no symptoms of autism/ADHD. In the video Professor Lundström gives the reasons for the misdiagnosis. It ranges from the parents insisting to have one, to the doctor giving one so that the child can access extra help at school. In many European countries the diagnosis qualifies the child/parents for various social security payments.

There are some downsides in Sweden to be an adult with an autism/ADHD diagnosis. It can affect employment, driving, or securing insurance.


The subject of ADHD leads to the second half of this post. Here we reconnect with the theme of treatable ion channel dysfunctions that have become somewhat a hallmark of this blog.

  

Calcium channel blockers now considered for ADHD treatment


 Blood pressure drug could be a safer alternative for treating ADHD symptoms, finds study

Repurposing amlodipine, a commonly used blood pressure medicine, could help manage attention-deficit/ hyperactivity disorder (ADHD) symptoms, according to an international study involving the University of Surrey.

 

Here is the full study

 

Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical records

ADHD is a chronic neurodevelopmental disorder that significantly affects life outcomes, and current treatments often have adverse side effects, high abuse potential, and a 25% non-response rate, highlighting the need for new therapeutics. This study investigates amlodipine, an L-type calcium channel blocker, as a potential foundation for developing a novel ADHD treatment by integrating findings from animal models and human genetic data. Amlodipine reduced hyperactivity in SHR rats and decreased both hyperactivity and impulsivity in adgrl3.1−/− zebrafish. It also crosses the blood-brain barrier, reducing telencephalic activation. Crucially, Mendelian Randomization analysis linked ADHD to genetic variations in L-type calcium channel subunits (α1-C; CACNA1C, β1; CACNB1, α2δ3; CACNA2D3) targeted by amlodipine, while polygenic risk score analysis showed symptom mitigation in individuals with high ADHD genetic liability. With its well-tolerated profile and efficacy across species, supported by genetic evidence, amlodipine shows potential to be refined and developed into a novel treatment for ADHD.

 

This is not an entirely new finding, but prior research shows that crossing the blood barrier is a key factor. Drugs like Verapamil win over Amlodipine.

 

Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders 

Calcium channel blockers (CCBs) differ in their ability to penetrate into the brain. Pharmacoepidemiological studies suggest that CCBs as a class may have beneficial effects on the risks and outcomes of some psychiatric and neurological disorders. It is plausible but unknown whether this effect relates to their brain penetrance. To address this, we used the TriNetX electronic health records network to identify people prescribed a brain-penetrant CCB (BP-CCB), or those given amlodipine, a CCB with low brain penetrability. We created cohorts of patients who, prior to first CCB exposure, either had to have, or could not have had, a recorded ICD-10 diagnosis in any of the following categories: psychotic disorder; affective disorder (including bipolar disorder and major depressive disorder); anxiety disorder; substance use disorder; sleep disorder; delirium; dementia, or movement disorder. Cohort pairs were propensity score matched for age, sex, race, blood pressure, body mass index, and a range of other variables. The outcomes were the incidence of these disorders measured over a two-year exposure period. Matched cohort sizes ranged from 17,896 to 49,987. In people with no prior history of psychiatric or neurodegenerative disorder, there was a significantly lower incidence of most disorders with BP-CCBs compared to amlodipine, with risk ratios ranging from 0.64 to 0.88 and an overall risk ratio of 0.88, i.e. a risk reduction of 12%. In people who did have a prior psychiatric or neurodegenerative diagnosis, differences were much smaller, but again showed lower risks for several disorders with BP-CCBs compared to amlodipine. The differences were somewhat more marked in women and in people less than 60 years old. Results were similar when comparing BP-CCBs with verapamil and diltiazem. We also compared BP-CCBs with angiotensin receptor blockers, and found an overall risk ratio of 0.94 in favour of BP-CCBs, but with differential effects across disorders including a higher risk of psychotic disorder and dementia, but a lower risk for anxiety and sleep disorders. In some analyses, there was evidence of residual confounding even after the extensive matching, in that negative control outcomes showed a reduced incidence with BP-CCBs relative to the comparator cohort. In summary, CCBs that readily penetrate the brain are associated with a lower incidence of neuropsychiatric disorders, especially first diagnoses, compared to CCBs which do not. This may reflect their blockade of neuronal voltage-gated calcium channels. The findings encourage repurposing trials using existing BP-CCBs, and suggest that novel BP-CCBs with enhanced and more selective central actions might have greater therapeutic potential for psychiatric and neurodegenerative disorders.

  

Conclusion

I do not think de-diagnosis of autism/ADHD will catch on in the UK or US. Few countries have a centralized register of who has autism/ADHD and in general there are few downsides to adults holding a diagnosis, unlike in Sweden. If it affected your rights to drive a car and what you pay for insurance, there would be a long queue for de-diagnosis.

In the Swedish military conscription/assessment medical guidelines, autism spectrum disorders are listed among psychiatric/neurological conditions that can lead to exemption from service. Some patriotic young Swedes with autism/ADHD actually want to serve.

As conscription may return to other less patriotic European countries, you can expect an additional demand for adult autism diagnosis to avoid the draft!

When it comes to calcium channels, I think all bases have already been well covered in this blog.

I know of several different calcium and other channel blockers being used by readers, the latest being Journavx/suzetrigine, a new one approved in 2025, which blocks Nav1.8. Nicardipine is more likely to block Nav1.8 in the brain. Journavx was developed specifically to have poor CNS penetration to avoid central side effects. It targets acute pain situations where short-term opioid use would normally be considered. It all depends which Nav1.8 channels you want to block. But, if the blood brain barrier is impaired (as we know it is in certain types of autism) then more of the drug will enter the brain than expected.

An impaired blood brain barrier would also help Amlodipine to cross.

 

Regular readers of this blog will already know that calcium channels are dysfunctional across a wide range of disorders from bipolar, schizophrenia, autism, intellectual disability to epilepsy.

I was nonetheless surprised that a university in the United Kingdom would propose repurposing Amlodipine (an L type calcium channel blocker) to treat ADHD. Even if they are mistaken, at least they are showing signs of curiosity!

There is no single perfect calcium channel blocker for the brain.

If you want to target Cav1.2 you have a great option in Verapamil, because it is relatively selective for this channel and it crosses the blood brain barrier easily.

If you want to target Cav1.2 and Cav1.3 then Amlodipine appears the best drug, but it does not cross the blood brain barrier as well as Verapamil.

I think the ADHD researchers should start with Cav1.2, because we know 100% it can be blocked in the brain using Verapamil. Then compare the result with taking Amlodipine.

 

Pleiotropic Association of CACNA1C Variants With Neuropsychiatric Disorders

 

From this blog we know that both verapamil and amlodipine can be safely used in autism. A small number of people do have side effects and discontinue, but most do not have issues.

The effect of the two drugs overlap but are not identical. This matches what we know about what channels they block. Verapamil also has other effects:

·        Verapamil partially blocks Cav1.3

·        Verapamil partially blocks T-type channels (Cav3.1–3.3) particularly at higher doses.

·        Verapamil partially blocks potassium Kv channels.

The big advantage of Amlodipine is that it has a long half-life, so you take it once a day.

Verapamil needs to be taken 3 times a day, or in the extended release version.

I did look on Reddit and plenty of people with ADHD were commenting that taking Amlodipine for high blood pressure had not improved their ADHD symptoms.

Note that ADHD is another umbrella diagnosis and there will be many sub-types. For some people Amlodipine might well help. For some people ADHD is just a consequence of being glued to a smartphone all day, every day, for years on end. Guess what, 60% of adults with ADHD report chronic sleep problems.

The over liberal diagnosis of autism in Stockholm does look crazy. Maybe it is the Greta effect?

It is as if Stockholm has developed a new version of the old “Stockholm syndrome” — an emotional loyalty to the very diagnostic culture now being questioned. When 90% of adults seeking de-diagnosis are found not to have autism or ADHD, it suggests that what began as a well-meaning effort to help children may have trapped an entire system in its own narrative. Fancy that.

 

(The term “Stockholm syndrome” comes from a 1973 bank robbery in Stockholm, when hostages ended up sympathising with their captors — a classic case of misplaced loyalty.)